株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

JAKおよびPI3Kシグナル伝達経路に関連する治療薬の市場

JAK and PI3K Signaling Pathway Markets

発行 BCC Research 商品コード 299706
出版日 ページ情報 英文 143 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.18円で換算しております。

2016年12月31日まで 年末キャンペーン割引: BCC Research社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
JAKおよびPI3Kシグナル伝達経路に関連する治療薬の市場 JAK and PI3K Signaling Pathway Markets
出版日: 2014年04月18日 ページ情報: 英文 143 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

JAK(ヤヌスキナーゼ)およびPI3K(ホスホイノシチド3キナーゼ)などの複雑なシグナル伝達経路に関する研究は、この数年で急速に進展しています。また、これらの経路の異常なシグナルに対応する治療薬や阻害剤の分離という点でも大きな進歩が見られました。JAKとPI3Kの細胞シグナル伝達経路に対応する治療薬開発の焦点は、骨髄線維症治療薬ruxolitinibや関節リウマチ治療薬tofacitinibの承認後、がん株や炎症性疾患に移っており、ぜんそく、皮膚病、呼吸器疾患、眼疾患などに対する治療薬の研究も進められています。シグナル伝達経路に関連する治療技術の研究は、がんや炎症性疾患などを標的とした治療薬の開発につながると期待されており、今のところこの分野には適切な医薬品がないため、市場が大きく成長する可能性もあります。

当レポートは、JAKとPI3K阻害剤/治療薬/バイオマーカーの有望な用途分野について検討し、世界市場におけるビジネスチャンス、標的となる疾病、臨床開発の進捗状況などを明らかにしたもので、規制面の問題や新薬開発の現状、各種市場の分析、特許についての分析、主要企業のプロファイルなども盛り込み、概略以下の構成でお届けします。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 概要

  • ヤヌスキナーゼ(JAK)とホスホイノシチド3キナーゼ(PI3K)
  • JAKとPI3Kに対応するシグナル伝達治療薬/阻害剤
  • 分類
  • JAKとPI3Kに対応するシグナル伝達バイオマーカー
  • JAKとPI3K治療薬の標的となる可能性のある疾病

第4章 規制の諸側面

  • ruxolitinib(INC424)
  • tafacitinib(CP-690、550)
  • シグナル伝達系治療薬/阻害剤/バイオマーカーに関する規制の整備

第5章 新薬開発

  • 新たな動き
  • 共同治験と今後の動き

第6章 市場分析−シグナル伝達系治療薬(JAKとPI3K)

  • 各種製品の市場
  • 世界各地域の市場
  • 将来的に有望な市場
  • 業界の構造
  • 主な用途
  • 有望な応用分野
    • がん
    • 炎症性疾患
    • 慢性心疾患
    • その他

第7章 特許分析

  • 2011年〜2013年に承認された特許
  • 各種治療薬の特許
  • JAKおよびPI3Kベース治療薬の特許
  • 各国で承認された特許
  • 譲受人の状況

第8章 市場の現状

  • 新たな技術とプラットフォーム
  • 市場に影響を及ぼしている要因
  • 市場の成長促進要因
  • 協力/買収

第9章 主要企業のプロファイル

  • ABBVIE INC.
  • AETERNA ZENTARIS INC.
  • AMGEN INC
  • アステラス製薬
  • ASTEX PHARMACEUTICALS INC
  • ASTRAZENECA PLC
  • BAYER HEALTHCARE PHARMACEUTICALS
  • CELL THERAPEUTICS INC
  • CURIS INC.
  • 第一三共
  • ELI LILLY AND CO.
  • EXELIXIS INC.
  • GALAPAGOS NV
  • GENENTECH INC
  • GILEAD SCIENCES INC.
  • GLAXOSMITHKLINE
  • INCYTE CORP.
  • INFINITY PHARMACEUTICALS INC.
  • ITALFARMACO S.P.A.
  • JANSSEN BIOTECH INC.
  • MEI PHARMA INC.
  • MERCK & CO. INC.
  • MILLENNIUM
  • NATIONAL CANCER INSTITUTE
  • 日本全薬工業
  • NOVARTIS INTERNATIONAL AG
  • NS PHARMA, INC
  • ONCOTHYREON INC
  • PATHWAY THERAPEUTICS LTD
  • PFIZER
  • PIRAMAL ENTERPRISES LIMITED
  • PORTOLA PHARMACEUTICALS INC
  • RIGEL PHARMACEUTICALS INC.
  • SANOFI ONCOLOGY
  • TEVA PHARMACEUTICALS INDUSTRIES LTD
  • TG THERAPEUTICS INC.
  • VERASTEM INC.
  • VERTEX PHARMACEUTICALS INC
  • WILEX AG
  • XCOVERY HOLDING COMPANY, LLC

第10章 付録−略語

図表リスト

目次
Product Code: PHM168A

The global market for signal transduction therapies/inhibitors (JAK and PI3K) reached $173.5 million in 2012. This market is expected to grow to $464.5 million in 2013 and $2.2 billion in 2018 with a compound annual growth rate (CAGR) of 36.8% over the five-year period from 2013 to 2018.

This report provides:

  • An overview of the global market for signal transduction therapies and inhibitors
  • Analyses of global market trends, with data from 2012, estimates for 2013, and projections of CAGRs through 2018
  • Information on approved products such as Ruxolitnib, as well as others in devlopment
  • Discussion of the regulatory environment which is impacting development
  • Relevant patent analysis
  • Profiles of leading companies in the industry

STUDY OBJECTIVES

The intent of the report carried out by BCC Research was to assess, explore and envisage the market potential of signal transduction therapies and to review the advancement of the several candidates in their clinical developments for therapies concerning the aberrant signals through janus kinase (JAK) and phosphoinositide 3-kinases (PI3K) pathways. The emerging market analysis for the therapies associated with JAK and PI3K deviant cellular signals is brought together from the approved product performance, the notable clinical developments, the judicious collaborations for advancement of successful research, commercialization plans, huge market opportunities, etc.

The report establishes a balanced projection on the budding market of JAK and PI3K based signal transduction therapies with just two products ruxolitinib (Jakafi) and tofacitinib (Xaljanz). Ruxolitinib was approved in November 2011 for myelofibrosis while tofacitinib was approved in November 2012 for rheumatoid arthritis, respectively. The report also projects the future market for the said therapies, candidate details and their clinical development status, biomarker research, market leaders and market shares, profile of leading companies, collaboration and commercialization strategies, technology platforms and new developments, regulatory aspects, patent details, opportunities and challenges, and drivers and factors determining the signal transduction therapies market for JAK and PI3K.

The sales data for ruxolitinib and tofacitinib is secured from the germane sources that comprise the annual reports of the manufacturing companies and other data sources. Market analysis is conducted for the periods from 2011 until 2013. The report also presents the revenue forecast for the year 2018 with a drilled down analysis on the region wise data for North America (U.S. and Canada), Europe and emerging markets for the examined period.

REASONS FOR DOING THIS STUDY

Significant developments have come about in both the understanding of the complexity of signal transduction pathways such as JAK and PI3K over the past couple of years. At the same time, much progress occurred in the isolation of target specific therapies/inhibitors for the abnormal signals in those pathways. The therapies for JAK and PI3K cellular signal pathways predominantly focus on the cancer lines and inflammatory diseases after the approval of ruxolitinib (for myelofibrosis) and tofacitinib (for rheumatoid arthritis). Although other diseases categories like asthma, skin, respiratory and eye disorders are also being explored largely. The report portrays the prospective therapeutic application of the JAK and PI3K inhibitors/therapies/biomarkers from the perspective of their market opportunity, disease targets, clinical development progress, etc.

The growing market of therapies related to JAK and PI3K signal pathways have tremendous opportunity to grow since these therapies have the potential to target diseases like cancer and inflammatory diseases with no appropriate medications so far. The current therapies are capable of reducing the disease burden but cannot cure. Furthermore, there is a growing patient base worldwide for cancers and inflammatory diseases.

SCOPE OF THE STUDY

BCC Research conducted the market evaluation, the global and regional breakdown of sales data, present and prospective application of the therapies, market forecasting, success and challenges, patent details, regulatory facet, clinical developments, market leaders and market share of the maturing market for JAK and PI3K inhibitors/therapies/biomarkers.

The sales data for the global and regional markets is validated for the present and projected values through scientific and statistical analysis. The information regarding the approved products and candidates as well as the technologies/platforms are provided based on their present/prospective application and viability.

ABOUT THE AUTHOR

A team of professionals in the biotechnology industry carried out this study. The project manager is Shalini S. Dewan, who holds a master's degree in pharmaceutical chemistry and has over 14 years of industry experience. Among the research topics she has covered are studies on compounds of potential pharmaceutical interest, from ibuprofen to 2-naphthyl acetic acid. Shalini was awarded a Gold Medal by the Prime Minister of India for her work and has worked with top companies in India and in the U.S.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY OBJECTIVES
  • REASONS FOR DOING THIS STUDY
  • CONTRIBUTIONS OF THE STUDY AND FOR WHOM
  • SCOPE OF THE STUDY
  • METHODOLOGY
  • INFORMATION SOURCES
  • ABOUT THE AUTHOR
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 - EXECUTIVE SUMMARY

  • SUMMARY TABLE: GLOBAL REVENUE OF SIGNAL TRANSDUCTION
  • THERAPIES/INHIBITORS (JAK AND PI3K), THROUGH 2018 ($ MILLIONS)
  • SUMMARY FIGURE: GLOBAL REVENUE OF SIGNAL TRANSDUCTION
  • THERAPIES/INHIBITORS (JAK AND PI3K), 2011-2018) ($ MILLIONS)

CHAPTER 3 - OVERVIEW

  • JANUS KINASE (JAK) AND PHOSPHOINOSITIDE 3-KINASES (PI3K)
  • SIGNAL TRANSDUCTION THERAPIES/INHIBITORS FOR JAK AND PI3K
    • MECHANISM OF ACTION
      • Janus Kinase Therapies/Inhibitors
      • Phosphoinositide 3-kinases (PI3K) Therapies/Inhibitors
    • APPROVED HISTONE DEACETYLASE INHIBITORS
  • CLASSIFICATION
    • JANUS KINASE (JAK)
      • TABLE 1: CLASSIFICATION OF JANUS KINASE (JAK)
  • PHOSPHOINOSITIDE 3-KINASES (PI3K)
    • TABLE 2: CLASSIFICATION OF PHOSPHOINOSITIDE 3-KINASES (PI3K)
  • JANUS KINASE THERAPIES/INHIBITORS
    • Ruxolitinib (INC424/INCB18424)
      • FIGURE 1: STRUCTURE OF INC424 (RUXOLITINIB)
    • Tofacitinib (CP-690,550)
      • FIGURE 2: STRUCTURE OF CP-690,550 (TOFACITINIB)
    • Baricitinib (INC28050/LY3009104)
      • FIGURE 3: STRUCTURE OF BARICITINIB (INC28050/LY3009104)
    • NS-018
    • Momelotinib (CYT-387)
      • FIGURE 4: STRUCTURE OF MOMELOTINIB (CYT-387)
    • AT9283
      • FIGURE 5: STRUCTURE OF AT9283
    • Pacritinib (SB1518)
      • FIGURE 6: STRUCTURE OF PACRITINIB (SB1518)
    • LY2784544
      • FIGURE 7 STRUCTURE OF LY2784544
    • TG101348 (SAR302503)
      • FIGURE 8: STRUCTURE OF TG101348 (SAR302503)
    • BMS911543
      • FIGURE 9: STRUCTURE OF BMS911543
    • Lestaurtinib (CEP-701)
      • FIGURE 10: STRUCTURE OF LESTAURTINIB (CEP-701)
    • LS104
    • WP1066
      • FIGURE 11: STRUCTURE OF WP1066
    • AG490
      • FIGURE 12: STRUCTURE OF AG490
    • AZD1480
      • FIGURE 13: STRUCTURE OF AZD1480
    • INCB39110
    • INCB47986
  • PHOSPHOINOSITIDE 3-KINASES (PI3K) THERAPIES/INHIBITORS
    • Wortmannin
      • FIGURE 14: STRUCTURE OF WORTMANNIN
    • Perifosine (KRX-0401)
      • FIGURE 15: STRUCTURE OF PERIFOSINE (KRX-0401)
    • LY294002
      • FIGURE 16: STRUCTURE OF LY294002
    • Idelalisib (GS-1101, CAL-101)
      • FIGURE 17: STRUCTURE OF IDELALISIB (GS-1101, CAL-101)
    • PX-866
      • FIGURE 18: STRUCTURE OF PX-866
    • IPI-145
      • FIGURE 19: STRUCTURE OF IPI-145
    • BKM120
      • FIGURE 20: STRUCTURE OF BKM120
    • Copanlisib (BAY80-6946)
      • FIGURE 21: STRUCTURE OF COPANLISIB (BAY 80-6946)
    • PF-05212384 (PKI-587)
      • FIGURE 22: STRUCTURE OF PF-05212384 (PKI-587)
    • Pictilisib (GDC-0941)
      • FIGURE 23: STRUCTURE OF PICTILISIB (GDC-0941)
    • Dactolisib (BEZ235)
      • FIGURE 24: STRUCTURE OF DACTOLISIB (BEZ235)
    • Apitolisib (GDC-0980)
      • FIGURE 25: STRUCTURE OF APITOLISIB (GDC-0980)
    • ZSTK474
      • FIGURE 26: STRUCTURE OF ZSTK474
    • SAR245409 (XL765)
      • FIGURE 27: STRUCTURE OF SAR245409 (XL765)
    • SAR245408 (XL147)
      • FIGURE 28: STRUCTURE OF APITOLISIB SAR245408 (XL147)
    • BYL719
      • FIGURE 29: STRUCTURE OF APITOLISIB BYL719
  • SIGNAL TRANSDUCTION BIOMARKERS FOR JAK AND PI3K
    • PROSPECTIVE DISEASE TARGETS FOR JAK AND PI3K THERAPIES
      • TABLE 3: SIGNAL TRANSDUCTION THERAPIES/INHIBITORS - PROSPECTIVE DISEASE TARGETS

CHAPTER 4 - REGULATORY ASPECTS

  • RUXOLITINIB (INC424)
    • DOSING INFORMATION
      • Dose Modifications
    • SAFETY INFORMATION
      • Safety of Ruxolitinib in Specific Population
    • RISK OF INFECTION
      • Tuberculosis
      • Progressive Multifocal Leukoencephalopathy (PML)
      • Herpes Zoster
  • TOFACITINIB (CP-690,550)
    • DOSING INFORMATION
      • Dose Modifications
    • SAFETY INFORMATION
      • Safety of Tofacitinib in Specific Populations
    • RISK OF INFECTION
      • Tuberculosis
    • REGULATORY DEVELOPMENTS OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS

CHAPTER 5 - NEW DEVELOPMENTS

  • NEW DEVELOPMENTS
    • TABLE 4: NEW DEVELOPMENTS IN THE RESEARCH PIPELINE OF SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) AS SINGLE AGENT
    • TABLE 5: NEW DEVELOPMENTS IN THE RESEARCH PIPELINE OF SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) IN COMBINATION WITH OTHER AGENTS
    • TABLE 6: NUMBER OF ONGOING TRIALS FOR MAJOR SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) AS SINGLE AGENT AND COMBINATION THERAPY
  • COLLABORATIVE TRIALS AND FUTURE ACTIVITIES

CHAPTER 6 - MARKET ANALYSIS-SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K)

  • MARKET BY THE TYPE
    • TABLE 7: GLOBAL MARKET FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY TYPE, THROUGH 2018 ($ MILLIONS)
    • FIGURE 30: GLOBAL MARKET FOR SIGNAL TRANSDUCTION
  • THERAPIES/INHIBITORS/BIOMARKERS BY TYPE, 2011-2018
    • RUXOLITINIB (INC424, INCB18424)-JANUS KINASE (JAK) INHIBITOR
      • Market Overview
      • Market Revenue
        • TABLE 8: GLOBAL MARKET FOR RUXOLITINIB (INC424, INCB18424, JAKAFI) BY REGION, THROUGH 2018 ($ MILLIONS)
        • FIGURE 31: GLOBAL MARKET FOR RUXOLITINIB (INC424, INCB18424, JAKAFI) BY REGION, 2011-2018 ($ MILLIONS)
    • TOFACITINIB (CP-690,550)-JANUS KINASE (JAK) INHIBITOR
      • Market Overview
      • Market Revenue 75
        • TABLE 9: GLOBAL MARKET FOR TOFACITINIB (CP-690,550) BY REGION, THROUGH 2018 ($ MILLIONS)
        • FIGURE 32: GLOBAL MARKET FOR TOFACITINIB (CP-690,550) BY REGION, 2011-2018 ($ MILLIONS)
  • MARKET SHARE
    • TABLE 10: MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY TYPE, 2013 (%)
    • FIGURE 33: MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY TYPE, 2013 (%)
  • MARKET BY REGION
    • MARKET OVERVIEW
    • MARKET REVENUE
      • TABLE 11: REGIONAL BREAKDOWN FOR SALES OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS, THROUGH 2018 ($ MILLIONS)
      • FIGURE 34: REGIONAL BREAKDOWN FOR SALES OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS, 2011-2018 ($ MILLIONS)
    • MARKET SHARE
      • TABLE 12: MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY REGION, 2013 ($ MILLIONS)
      • FIGURE 35: MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY REGION, 2013 ($ MILLIONS)
  • PROSPECTIVE FUTURE MARKET FOR SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K)
    • INDUSTRY STRUCTURE
    • MARKET LEADERS
      • TABLE 13: LEADING MANUFACTURERS/SUPPLIERS OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS
    • MARKET SHARES
      • TABLE 14: MARKET SHARES OF MANUFACTURERS FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS, 2013 (%)
      • FIGURE 36: MARKET SHARES OF MANUFACTURERS FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS, 2013 (%)
    • MARKET APPLICATIONS
      • TABLE 15: APPLICATION AREAS OF COMBINATION THERAPY OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS (FOR JAK AND PI3K) WITH OTHER THERAPIES
  • MYELOFIBROSIS
  • RHEUMATOID ARTHRITIS
    • MARKET OVERVIEW
    • MARKET REVENUE
      • TABLE 16: GLOBAL MARKET FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K) BY TYPE, THROUGH 2018 ($ MILLIONS)
      • FIGURE 37: GLOBAL MARKET FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K) BY TYPE, 2011-2018 ($ MILLIONS)
    • MARKET SHARE
      • TABLE 17: MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K) BY APPLICATION, 2013 (%)
      • FIGURE 38: MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K) BY APPLICATION, 2013 (%)
  • PROSPECTIVE APPLICATION OF SIGNAL TRANDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K)
    • CANCER
    • INFLAMMATORY DISEASES
    • CARDIAC AILMENTS
    • OTHERS

CHAPTER 7 - PATENT ANALYSIS

  • PATENTS BY YEAR
    • TABLE 18: TOTAL NUMBER OF PATENTS EACH YEAR, 2011-2013
    • FIGURE 39: TOTAL NUMBER OF PATENTS EACH YEAR, 2011-2013
  • PATENTS BY SIGNAL TRANSDUCTION THERAPIES CATEGORY (JAK AND PI3K)
    • TABLE 19: NUMBER OF PATENTS BY SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS CATEGORY, 2011-2013
    • FIGURE 40: NUMBER OF PATENTS BY SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS CATEGORY, 2011-2013
  • PATENTS BY SIGNAL TRANSDUCTION THERAPIES TYPE
    • PATENTS BY JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS
      • TABLE 20: PATENTS BY TYPES OF JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
      • FIGURE 4:1 PATENTS BY TYPES OF JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
    • PATENTS BY PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS
      • TABLE 21: PATENTS BY TYPES OF PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
      • FIGURE 42: PATENTS BY TYPES OF PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
  • PATENTS BY COUNTRY
    • JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS
      • TABLE 22: NUMBER OF PATENTS BY COUNTRY FOR JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
      • FIGURE 43: NUMBER OF PATENTS BY COUNTRY FOR JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
      • TABLE 23: PATENT SHARES BY COUNTRY FOR JANUS KINASE BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013 (%)
      • FIGURE 44: PATENT SHARES BY COUNTRY FOR JANUS KINASE BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013 (%)
    • PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS
      • TABLE 24: NUMBER OF PATENTS BY COUNTRY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
      • FIGURE 45: NUMBER OF PATENTS BY COUNTRY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
      • TABLE 25: PATENT SHARES BY COUNTRY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013 (%)
      • FIGURE 46: PATENT SHARES BY COUNTRY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013 (%)
  • PATENTS BY COMPANY
    • JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS
      • TABLE 26: NUMBER OF U.S. PATENTS BY COMPANY FOR JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
    • PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS
      • TABLE 27: NUMBER OF U.S. PATENTS BY COMPANY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
  • PATENTS BY ASSIGNEE
    • JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS
      • TABLE 28: PATENTS BY ASSIGNEE FOR JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
      • FIGURE 47: PATENTS BY ASSIGNEE FOR JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
    • PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS
      • TABLE 29: PATENTS BY ASSIGNEE FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
      • FIGURE 48: PATENTS BY ASSGINEE FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013

CHAPTER 8 - CURRENT SITUATION

  • NEW TECHNOLOGIES AND PLATFORMS IN SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K)
    • SCREENING TECHNOLOGY
    • PYRAMID
    • BIOMARKERS
  • FACTORS AFFECTING THE SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) MARKET
  • CURRENT DRIVERS OF SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) MARKET
    • COLLABORATIONS/ACQUISITIONS
      • TABLE 30: FUNDINGS IN SIGNAL TRANDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K)

CHAPTER 9 - COMPANY PROFILES

  • ABBVIE INC.
  • AETERNA ZENTARIS INC.
  • AMGEN INC
  • ASTELLAS PHARMA INC.
  • ASTEX PHARMACEUTICALS INC
  • ASTRAZENECA PLC
  • BAYER HEALTHCARE PHARMACEUTICALS
  • CELL THERAPEUTICS INC
  • CURIS INC.
  • DAIICHI SANKYO CO. LTD
  • ELI LILLY AND CO.
  • EXELIXIS INC.
  • GALAPAGOS NV
  • GENENTECH INC
  • GILEAD SCIENCES INC.
  • GLAXOSMITHKLINE
  • INCYTE CORP.
  • INFINITY PHARMACEUTICALS INC.
  • ITALFARMACO S.P.A.
  • JANSSEN BIOTECH INC.
  • MEI PHARMA INC.
  • MERCK & CO. INC.
  • MILLENNIUM
  • NATIONAL CANCER INSTITUTE
  • NIPPON ZENYAKU KOGYO CO., LTD.
  • NOVARTIS INTERNATIONAL AG
  • NS PHARMA, INC
  • ONCOTHYREON INC
  • PATHWAY THERAPEUTICS LTD
  • PFIZER
  • PIRAMAL ENTERPRISES LIMITED
  • PORTOLA PHARMACEUTICALS INC
  • RIGEL PHARMACEUTICALS INC.
  • SANOFI ONCOLOGY
  • TEVA PHARMACEUTICALS INDUSTRIES LTD
  • TG THERAPEUTICS INC.
  • VERASTEM INC.
  • VERTEX PHARMACEUTICALS INC
  • WILEX AG
  • XCOVERY HOLDING COMPANY, LLC

CHAPTER 10 - APPENDIX I-ABBREVIATIONS

LIST OF TABLES

  • SUMMARY TABLE: GLOBAL REVENUE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS (JAK AND PI3K), THROUGH 2018 ($ MILLIONS)
    • TABLE 1: CLASSIFICATION OF JANUS KINASE (JAK)
    • TABLE 2: CLASSIFICATION OF PHOSPHOINOSITIDE 3-KINASES (PI3K)
    • TABLE 3: SIGNAL TRANSDUCTION THERAPIES/INHIBITORS - PROSPECTIVE DISEASE TARGETS
    • TABLE 4: NEW DEVELOPMENTS IN THE RESEARCH PIPELINE OF SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) AS SINGLE AGENT
    • TABLE 5: NEW DEVELOPMENTS IN THE RESEARCH PIPELINE OF SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) IN COMBINATION WITH OTHER AGENTS
    • TABLE 6: NUMBER OF ONGOING TRIALS FOR MAJOR SIGNAL TRANSDUCTION THERAPIES (JAK AND PI3K) AS SINGLE AGENT AND COMBINATION THERAPY
    • TABLE 7: GLOBAL MARKET FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY TYPE, THROUGH 2018 ($ MILLIONS)
    • TABLE 8: GLOBAL MARKET FOR RUXOLITINIB (INC424, INCB18424, JAKAFI) BY REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 9: GLOBAL MARKET FOR TOFACITINIB (CP-690,550) BY REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 10: MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY TYPE, 2013 (%)
    • TABLE 11: REGIONAL BREAKDOWN FOR SALES OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS, THROUGH 2018 ($ MILLIONS)
    • TABLE 12: MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY REGION, 2013 ($ MILLIONS)
    • TABLE 13: LEADING MANUFACTURERS/SUPPLIERS OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS
    • TABLE 14: MARKET SHARES OF MANUFACTURERS FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS, 2013 (%)
    • TABLE 15: APPLICATION AREAS OF COMBINATION THERAPY OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS (FOR JAK AND PI3K) WITH OTHER THERAPIES
    • TABLE 16: GLOBAL MARKET FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K) BY TYPE, THROUGH 2018 ($ MILLIONS)
    • TABLE 17: MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K) BY APPLICATION, 2013 (%)
    • TABLE 18: TOTAL NUMBER OF PATENTS EACH YEAR, 2011-2013
    • TABLE 19: NUMBER OF PATENTS BY SIGNAL TRANSDUCTION THERAPIES/ INHIBITORS/BIOMARKERS CATEGORY, 2011-2013
    • TABLE 20: PATENTS BY TYPES OF JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
    • TABLE 21: PATENTS BY TYPES OF PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
    • TABLE 22: NUMBER OF PATENTS BY COUNTRY FOR JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
    • TABLE 23: PATENT SHARES BY COUNTRY FOR JANUS KINASE BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013 (%)
    • TABLE 24: NUMBER OF PATENTS BY COUNTRY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
    • TABLE 25: PATENT SHARES BY COUNTRY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013 (%)
    • TABLE 26: NUMBER OF U.S. PATENTS BY COMPANY FOR JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
    • TABLE 27: NUMBER OF U.S. PATENTS BY COMPANY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
    • TABLE 28: PATENTS BY ASSIGNEE FOR JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
    • TABLE 29: PATENTS BY ASSIGNEE FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
    • TABLE 30: FUNDINGS IN SIGNAL TRANDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K)

LIST OF FIGURES

  • SUMMARY FIGURE: GLOBAL REVENUE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS (JAK AND PI3K), 2011-2018) ($ MILLIONS)
    • FIGURE 1: STRUCTURE OF INC424 (RUXOLITINIB)
    • FIGURE 2: STRUCTURE OF CP-690,550 (TOFACITINIB)
    • FIGURE 3: STRUCTURE OF BARICITINIB (INC28050/LY3009104)
    • FIGURE 4: STRUCTURE OF MOMELOTINIB (CYT-387)
    • FIGURE 5: STRUCTURE OF AT9283
    • FIGURE 6: STRUCTURE OF PACRITINIB (SB1518)
    • FIGURE 7: STRUCTURE OF LY2784544
    • FIGURE 8: STRUCTURE OF TG101348 (SAR302503)
    • FIGURE 9: STRUCTURE OF BMS911543
    • FIGURE 10: STRUCTURE OF LESTAURTINIB (CEP-701)
    • FIGURE 11: STRUCTURE OF WP1066
    • FIGURE 12: STRUCTURE OF AG490
    • FIGURE 13: STRUCTURE OF AZD1480
    • FIGURE 14: STRUCTURE OF WORTMANNIN
    • FIGURE 15: STRUCTURE OF PERIFOSINE (KRX-0401)
    • FIGURE 16: STRUCTURE OF LY294002
    • FIGURE 17: STRUCTURE OF IDELALISIB (GS-1101, CAL-101)
    • FIGURE 18: STRUCTURE OF PX-866
    • FIGURE 19: STRUCTURE OF IPI-145
    • FIGURE 20: STRUCTURE OF BKM120
    • FIGURE 21: STRUCTURE OF COPANLISIB (BAY 80-6946)
    • FIGURE 22: STRUCTURE OF PF-05212384 (PKI-587)
    • FIGURE 23: STRUCTURE OF PICTILISIB (GDC-0941)
    • FIGURE 24: STRUCTURE OF DACTOLISIB (BEZ235)
    • FIGURE 25: STRUCTURE OF APITOLISIB (GDC-0980)
    • FIGURE 26: STRUCTURE OF ZSTK474
    • FIGURE 27: STRUCTURE OF SAR245409 (XL765)
    • FIGURE 28: STRUCTURE OF APITOLISIB SAR245408 (XL147)
    • FIGURE 29: STRUCTURE OF APITOLISIB BYL719
    • FIGURE 30: GLOBAL MARKET FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY TYPE, 2011-2018
    • FIGURE 31: GLOBAL MARKET FOR RUXOLITINIB (INC424, INCB18424, JAKAFI) BY REGION, 2011-2018 ($ MILLIONS)
    • FIGURE 32: GLOBAL MARKET FOR TOFACITINIB (CP-690,550) BY REGION, 2011-2018 ($ MILLIONS)
    • FIGURE 33: MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS BY TYPE, 2013 (%)
    • FIGURE 34: REGIONAL BREAKDOWN FOR SALES OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS, 2011-2018 ($ MILLIONS)
    • FIGURE 35: MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/ INHIBITORS/BIOMARKERS BY REGION, 2013 ($ MILLIONS)
    • FIGURE 36: MARKET SHARES OF MANUFACTURERS FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS, 2013 (%)
    • FIGURE 37: GLOBAL MARKET FOR SIGNAL TRANSDUCTION THERAPIES/INHIBITORS/BIOMARKERS (JAK AND PI3K) BY TYPE, 2011-2018 ($ MILLIONS)
    • FIGURE 38: MARKET SHARE OF SIGNAL TRANSDUCTION THERAPIES/ INHIBITORS/BIOMARKERS (JAK AND PI3K) BY APPLICATION, 2013 (%)
    • FIGURE 39: TOTAL NUMBER OF PATENTS EACH YEAR, 2011-2013
    • FIGURE 40: NUMBER OF PATENTS BY SIGNAL TRANSDUCTION THERAPIES/ INHIBITORS/BIOMARKERS CATEGORY, 2011-2013
    • FIGURE 41: PATENTS BY TYPES OF JANUS KINASE (JAK) BASED THERAPIES/ INHIBITORS/BIOMARKERS, 2011-2013
    • FIGURE 42: PATENTS BY TYPES OF PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
    • FIGURE 43: NUMBER OF PATENTS BY COUNTRY FOR JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
    • FIGURE 44: PATENT SHARES BY COUNTRY FOR JANUS KINASE BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013 (%)
    • FIGURE 45: NUMBER OF PATENTS BY COUNTRY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
    • FIGURE 46: PATENT SHARES BY COUNTRY FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013 (%)
    • FIGURE 47: PATENTS BY ASSIGNEE FOR JANUS KINASE (JAK) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
    • FIGURE 48: PATENTS BY ASSGINEE FOR PHOSPHOINOSITIDE 3-KINASES (PI3K) BASED THERAPIES/INHIBITORS/BIOMARKERS, 2011-2013
Back to Top